{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:42:13Z","timestamp":1780508533497,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T00:00:00Z","timestamp":1506470400000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatrics International"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Epstein\u2013Barr virus\u2010related post\u2010transplantation lymphoproliferative disease (<jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content>) is a serious complication in hematopoietic stem cell transplantation (<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>) recipients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective study to investigate the incidence and potential risk factors for <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content> reactivation and to assess the efficacy of the management of <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content> reactivation with pre\u2010emptive rituximab in children who had T\u2010cell\u2010replete haploidentical <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">TCR<\/jats:styled-content>\u2010haplo\u2010<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>) with low\u2010dose anti\u2010thymocyte globulin (<jats:styled-content style=\"fixed-case\">ATG<\/jats:styled-content>). <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> level in peripheral blood (<jats:styled-content style=\"fixed-case\">PB<\/jats:styled-content>) was measured when suspected <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content> reactivation were observed. When the <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> level in <jats:styled-content style=\"fixed-case\">PB<\/jats:styled-content> increased to &gt;1,000 copies\/10<jats:sup>6<\/jats:sup> peripheral blood mononuclear cells (<jats:styled-content style=\"fixed-case\">PBMC<\/jats:styled-content>), patients were pre\u2010emptively treated with rituximab (375\u00a0mg\/m<jats:sup>2<\/jats:sup>\/dose).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 19 (50%) of 38 patients received rituximab infusion at a median time of 56\u00a0days after <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> (range, 17\u2013270\u00a0days). The median viral load at initiation of therapy was 2,900 copies\/10<jats:sup>6<\/jats:sup> <jats:styled-content style=\"fixed-case\">PBMC<\/jats:styled-content> (range, 1,000\u2013650\u00a0000). Pre\u2010emptive therapy was started after a median of 2\u00a0days (range, 0\u20137\u00a0days). The median number of weekly treatment cycles was 2 (range, 1\u20133). None of the patients developed <jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content> or other <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010associated diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pre\u2010emptive rituximab therapy could be a useful strategy for <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">TCR<\/jats:styled-content>\u2010haplo\u2010<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> recipients with low\u2010dose <jats:styled-content style=\"fixed-case\">ATG<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ped.13336","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T09:50:37Z","timestamp":1496656237000},"page":"973-978","source":"Crossref","is-referenced-by-count":11,"title":["Pre\u2010emptive rituximab for Epstein\u2013Barr virus reactivation after haplo\u2010hematopoietic stem cell transplantation"],"prefix":"10.1111","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2305-942X","authenticated-orcid":false,"given":"Shogo","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology Fukushima Medical University School of Medicine Fukushima City Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology Fukushima Medical University School of Medicine Fukushima City Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology Fukushima Medical University School of Medicine Fukushima City Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology Fukushima Medical University School of Medicine Fukushima City Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology Fukushima Medical University School of Medicine Fukushima City Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ohto","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion and Transplantation Immunology Fukushima Medical University School of Medicine Fukushima City Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kikuta","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology Fukushima Medical University School of Medicine Fukushima City Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-143545"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.08.007"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4364"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.5.1346"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2005.00318.x"},{"key":"e_1_2_7_7_1","first-page":"1059","article-title":"The role of HLA mismatch, splenectomy and recipient Epstein\u2010Barr virus seronegativity as risk factors in post\u2010transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation","volume":"91","author":"Sundin M","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_8_1","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: A multi\u2010institutional study","volume":"94","author":"Curtis RE","year":"1999","journal-title":"Blood"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.035"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08904.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2010.01352.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12150"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703260"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit391"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144428"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.06.019"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239186"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2009.00411.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.28"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.26"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.10.003"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12061"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.302"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181e7a3bf"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31819f1c49"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00913-08"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2006.01936.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.087338"}],"container-title":["Pediatrics International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fped.13336","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ped.13336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:17:14Z","timestamp":1694719034000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ped.13336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/ped.13336"],"URL":"https:\/\/doi.org\/10.1111\/ped.13336","archive":["Portico"],"relation":{},"ISSN":["1328-8067","1442-200X"],"issn-type":[{"value":"1328-8067","type":"print"},{"value":"1442-200X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}